AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

US11207361B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• John A. Chiorini · Silver Spring, US
• Giovanni DiPasquale · Kensington, US
• Edoardo Mannucci · Prato, IT

Key dates

• Filing date: Apr 26, 2019
• Grant date: Dec 28, 2021
• Expiry date: Oct 3, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.